| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Journal of Clinical Microbiology, February 2008, p. 759-762, Vol. 46, No. 2
0095-1137/08/$08.00+0 doi:10.1128/JCM.02009-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Ron Berkhout,2
Wilma Vermeulen-Oost,2
Ronald Dijkman,1
Maarten F. Jebbink,1
Sylvia Bruisten,2
Ben Berkhout,1 and
Lia van der Hoek1*
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands,1 Public Health Laboratory, Municipal Health Service, Amsterdam, The Netherlands2
Received 12 October 2007/ Returned for modification 26 November 2007/ Accepted 4 December 2007
Picornavirus cultures that could not be typed in neutralization assays were analyzed by VP1 reverse transcription-PCR (RT-PCR) and a virus discovery tool (VIDISCA). Human parechoviruses (HPeVs) were frequently identified, among which were the uncommon isolates HPeV-4, HPeV-5, and HPeV-6. The HPeV-5 isolate could be amplified only by VIDISCA and not by VP1 RT-PCR.
Published ahead of print on 12 December 2007.
Current address: Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|